Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Lundbeck Opens $7.6 Million Production Plant in Tianjin

publication date: Nov 9, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Lundbeck A/S, the Danish CNS drugmaker, has opened a $7.6 million production plant in Tianjin, its first manufacturing facility in China. Lundbeck has been marketing its products in China for sixteen years. In 2010, Lundbeck opened an R&D center in Shanghai. The new Tianjin facility will initially manufacture the company’s treatment for Alzheimer’s disease, Ebixa. More details....

Stock Symbol: (CPH: LUN )

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners